Article
Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
Clinical and experimental immunology - 1 Apr 2017
Longhurst H J, Zanichelli A, Caballero T, Bouillet L, Aberer W, Maurer M, Fain O, Fabien V, Andresen I
Abstract excerpt
Icatibant is used to treat acute hereditary angioedema with C1 inhibitor deficiency types I/II (C1-INH-HAE types I/II) and has shown promise in angioedema due to acquired C1 inhibitor deficiency (C1-INH-AAE). Data from the Icatibant Outcome Survey (IOS) were analysed to evaluate the effectiveness of icatibant in the treatment of patients with C1-INH-AAE and compare disease characteristics with those with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.